Spotlight On... Suffering Eleven Bio gets a delisting notice from Nasdaq; Omeros spikes on orphan status, PhIII plans; Rigel names new CMO; and more...

After back-to-back clinical disasters pushed Eleven Biotherapeutics ($EBIO) into penny stock territory, Nasdaq says it's time to get squared away or move off the exchange. The Cambridge, MA-based biotech addressed the delisting notice from Nasdaq in an SEC filing, noting that its stock is trading under $1 a share and that stockholders' equity did not comply with the minimum stockholders' equity requirement of $5,000,000. The biotech now has 180 days to regain compliance with Nasdaq rules. SEC filing

@FierceBiotech: Eyeing the U.S. market, TiGenix touts 52-wk data from PhIII stem cell trial. Story | Follow @FierceBiotech

@JohnCFierce: I have a gut feeling that UC and The Broad are going to settle up on CRISPR. Excellent summary from STAT story | Follow @JohnCFierce

> Shares of Omeros ($OMER) were buoyed on Tuesday after the biotech reported that it had won orphan drug status and launched a late-stage program for its kidney therapy. Story

> Rigel Pharmaceuticals ($RIGL) named Anne-Marie Duliege to the role of chief medical officer, replacing Elliott Grossbard, who is retiring after 14 years with the company. Release

> Epizyme ($EPZM) outlined plans for the next 5 years of its business, looking to transition into a commercial operation and prepare for the potential approval of its lead cancer drug. More

> Sterop, a Belgian drugmaker, is accused of supplying ephedrine to Mexican drug cartels to be used in the production of methamphetamine. Story

> AstraZeneca's ($AZN) in-development cancer therapy MEDI-551 picked up the FDA's orphan drug designation for its potential in neuromyelitis optica, a rare autoimmune disorder. News

Medical Device News

@FierceMedDev: ICYMI yesterday: J&J's Ethicon to buy NeuWave for soft-tissue, microwave ablation for cancer. Article | Follow @FierceMedDev

@VarunSaxena2: Toyota developing wearable device to improve mobility for the blind. Report | Follow @VarunSaxena2

@EmilyWFierce: Duke University teams with NC State for new cancer drug development project in canines. FierceAnimalHealth story | Follow @EmilyWFierce

> BD forms $500M JV with private equity firm Apax to house ailing respiratory biz. Report

> Agilent to lay down $80M for large stake in sequencing company Lasergen. Story

> Canon in exclusive negotiations to acquire Toshiba Medical Systems, likely for around $6B. Article

Pharma News

@FiercePharma: South Korea's Green Cross to supply Americas with flu vaccine in $32M deal. FierceVaccines item | Follow @FiercePharma

@EricPFierce: More biologics manufacturing capacity comes online in the U.S. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Amgen is eyeing heftier deals, but so are its biggest rivals. Story | Follow @CarlyHFierce

> Orexigen takes another body blow from ill-fated Contrave trial. More

> With FDA settlement, tiny Amarin creates opening for pharma in off-label marketing. Story

> Surprise proposal: Medicare wants to jump on the value-based pricing bandwagon. Article

Pharma Marketing News

> Allergan rolls out third round of Linzess ads, targeting patients fed up with OTC meds. Report

> Fake smiles star in Otsuka and Lundbeck's DTC push for Rexulti in depression. Story

> Ill-fated Contrave trial piles more hurt on Orexigen. Item

> AbbVie's Humira, Pfizer's Lyrica kick off 2016 with hefty TV ad spend. Article

> Blind Pfizer sales rep gets her chance to argue for a car and driver in court. More

Biotech Research News

> MIT team spotlights role of amino acids in building tumor cells. Item

> Single gene mutation linked with significantly reduced heart attack risk. Report

> Mouse, tissue tests confirm a new pathway for insulin resistance in diabetes. Story

> Karolinska: Nanoparticle tech opens up new drug, vaccine targets. More

> Mount Sinai: CDK4/ARK5 inhibitor could offer new treatment for multiple myeloma. Article

Vaccines News

> Sanofi digs into details on hastened Zika effort. Story

> Vaxart, Immunovaccine, Mayo Clinic jump onto Zika vaccine bandwagon. More

> South Korea's Green Cross to supply Americas with flu vaccine in $32M deal. Item

> Duke, NIAID track HIV evolution with eyes on creating a vaccine. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.